A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac repolarization in patients with solid tumors who's cancer has recurred or is no longer responding to current treatment.
Condition or disease
Breast CancerOvarian CancerColon CancerLung CancerGastric CancerSolid Tumors
To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF) [ Time Frame: Electrocardiograms (ECGs) will be done at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 in triplicate, 1 time point on Day 2 of Periods 1, 2, and 3 and 1 time point on Day 3 of Period 3. ]
Secondary Outcome Measures :
Pharmacokinetic sampling maximum observed plasma concentration (Cmax) [ Time Frame: Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3. ]
Pharmacokinetic sampling - time to maximum observed plasma concentration (Tmax) [ Time Frame: Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3. ]
Pharmacokinetic sampling - the area under the plasma concentration-time curve (AUC) from time 0-24 hours (AUC 0-24) [ Time Frame: Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3. ]
The number of subjects with adverse events [ Time Frame: Up to 30 days after last dose of study drug. ]
Vital Signs [ Time Frame: Up to 30 days after last dose of study drug. ]
Blood pressure, heart rate and temperature.
Clinical Laboratory Tests [ Time Frame: Up to 30 days after last dose of study drug. ]
Hematology, chemistry, urinalysis
Tumor Assessment [ Time Frame: Screening ]
A computerized tomography scan will be done at screening to document tumor size.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 99 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Confirmed solid malignancy that is metastatic or unresectable for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective.
Subjects with brain metastases must have clinically controlled neurologic symptoms.
Subject is able to swallow and retain oral medications and does not have uncontrolled emesis.
Subject has adequate bone marrow, renal and hepatic function per local laboratory reference ranges.
Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2 hyponatremia or hypernatremia.
Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.
Subject has a history of cardiac conduction abnormalities.
Subject has a significant history of cardiovascular disease.
Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug, or has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy.
Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7 days prior to the first study dose.
Use of tobacco or nicotine-containing products within 12 hours prior to the first study dose.